Chardan Capital Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)
Chardan Capital has maintained a Buy rating on 4D Molecular Therapeutics (FDMT) with a price target of $26.00, according to analyst Geulah Livshits. Livshits, a 5-star analyst, has an average return of 22.2% and a 41.55% success rate. Other analysts, including Evercore ISI's Jonathan Miller, also rated FDMT as a Buy, while Morgan Stanley upgraded it to a Hold on November 6.
In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Buy rating on 4D Molecular Therapeutics, with a price target of $26.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Livshits is a 5-star analyst with an average return of 22.2% and a 41.55% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Lexeo Therapeutics, Inc., and Rocket Pharmaceuticals.
In addition to Chardan Capital, 4D Molecular Therapeutics also received a Buy from Evercore ISI’s Jonathan Miller in a report issued on November 7. However, on November 6, Morgan Stanley upgraded 4D Molecular Therapeutics (NASDAQ: FDMT) to a Hold.
